Fierce Biotech Mix Logo.png Fierce Biotech Mix Logo.png
Webinar

Beyond Amyloid: New Insights into Tau Pathology and Disease Progression with eMTBR

ET
60 Minutes

As research into Alzheimer’s disease and other neurological conditions evolves, blood-based biomarkers are providing new opportunities to better understand tau pathology and how it relates to disease progression. 

This webinar will examine emerging research on eMTBR-Tau as a blood-based marker of tau aggregation, including its relationship with tau PET staging and longitudinal clinical progression in Alzheimer’s disease. The discussion will also explore findings across other neurological conditions, offering a broader perspective on how tau-related biomarkers may help researchers characterize disease biology across different disease contexts. 

What you’ll learn: 

  • How eMTBR-Tau relates to tau PET staging and longitudinal clinical progression in Alzheimer’s disease 

  • What emerging research suggests about eMTBR-Tau across other neurological conditions 

  • How blood-based biomarkers may help characterize tau pathology and disease progression across neurodegenerative disorders 

Speakers

0

Nicholas Ashton, PhD

Sr. Director, Fluid Biomarker Program
Banner Health

Dr. Nicholas Ashton is Senior Director of the Banner Research Fluid Biomarker Program and a leading expert in the development and validation of fluid biomarkers for Alzheimer’s disease and related disorders. He has more than a decade of experience in biofluid analysis and assay development, spanning discovery mass spectrometry to ultrasensitive immunoassays. Dr. Ashton earned his PhD from King’s College London and is an Associate Professor at the University of Gothenburg. He has published more than 200 research articles and has been recognized as a Clarivate Highly Cited Researcher. His work focuses on advancing blood- and cerebrospinal fluid-based biomarkers for neurodegenerative disease research and clinical use.

0

Sang Won Seo, MD

Professor of Neurology
Samsung Medical Center

Sang Won Seo is a Professor of Neurology at Samsung Medical Center, Sungkyunkwan University School of Medicine. He leads the multicentre K-ROAD cohort and Korea’s Trial Ready Registry. His research focuses on Alzheimer’s disease biomarkers and neuroimaging, with a particular interest in plasma proteomics for understanding disease progression and treatment responses.

Register here!

Already registered? Click here to login.
Date/Time:
ET